Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
26
07
2019
accepted:
11
02
2020
pubmed:
3
3
2020
medline:
15
5
2021
entrez:
3
3
2020
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic, debilitating disease with a considerable effect on patient quality of life. Its clinical severity can be measured using different scoring systems; however, few of them include patient-centred parameters. To create a new scoring system for HS that includes a quality-of-life instrument, the HIDRAdisk. This post hoc analysis was carried out within the framework of a multicentre, longitudinal, epidemiologic study conducted over 9 months on quality-of-life aspects of HS. The new severity score was created using as reference a question from the Subject Satisfaction Questionnaire (SSQ) concerning the severity of HS as evaluated by the patient. Associated variables were selected using univariable and multivariable logistic regression models. The discriminant capabilities of the final model and of the final score were evaluated by the area under the receiver operating characteristic curve and the Hosmer-Lemeshow test. The study population included 308 patients with HS of any severity grade. According to the results of the regression models, the variables associated with the reference SSQ measure were number of inflammatory nodules, abscesses and draining fistulas; the HIDRAdisk score; and the number of subumbilical lesions. The HIDRAscore is obtained by the sum of the scores associated with the number of these parameters. Possible scores range from 0 to 10. The HIDRAscore is a new scoring system for HS severity which, in addition to the clinical evaluation by the physician, includes a validated patient-reported outcome measure, the HIDRAdisk.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic, debilitating disease with a considerable effect on patient quality of life. Its clinical severity can be measured using different scoring systems; however, few of them include patient-centred parameters.
OBJECTIVE
OBJECTIVE
To create a new scoring system for HS that includes a quality-of-life instrument, the HIDRAdisk.
METHODS
METHODS
This post hoc analysis was carried out within the framework of a multicentre, longitudinal, epidemiologic study conducted over 9 months on quality-of-life aspects of HS. The new severity score was created using as reference a question from the Subject Satisfaction Questionnaire (SSQ) concerning the severity of HS as evaluated by the patient. Associated variables were selected using univariable and multivariable logistic regression models. The discriminant capabilities of the final model and of the final score were evaluated by the area under the receiver operating characteristic curve and the Hosmer-Lemeshow test.
RESULTS
RESULTS
The study population included 308 patients with HS of any severity grade. According to the results of the regression models, the variables associated with the reference SSQ measure were number of inflammatory nodules, abscesses and draining fistulas; the HIDRAdisk score; and the number of subumbilical lesions. The HIDRAscore is obtained by the sum of the scores associated with the number of these parameters. Possible scores range from 0 to 10.
CONCLUSION
CONCLUSIONS
The HIDRAscore is a new scoring system for HS severity which, in addition to the clinical evaluation by the physician, includes a validated patient-reported outcome measure, the HIDRAdisk.
Identifiants
pubmed: 32119143
doi: 10.1111/jdv.16328
pmc: PMC7607398
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1815-1821Subventions
Organisme : AbbVie
Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Med Care. 1989 Mar;27(3 Suppl):S110-27
pubmed: 2646486
Wounds. 2015 Oct;27(10):258-64
pubmed: 26479209
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
J Am Acad Dermatol. 2007 Apr;56(4):621-3
pubmed: 17097366
Br J Dermatol. 2017 Nov;177(5):1401-1409
pubmed: 28636793
Dermatology. 2016;232(6):687-691
pubmed: 28052274
Cutis. 2017 Mar;99(3):156-157
pubmed: 28398416
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e24-e26
pubmed: 29894009
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):766-773
pubmed: 30633405
Dermatology. 2018;234(1-2):71-78
pubmed: 29758553
Ann Intern Med. 2012 Dec 18;157(12):846-55
pubmed: 23247938
J Invest Dermatol. 2004 Mar;122(3):602-7
pubmed: 15086541
Am J Clin Dermatol. 2015 Feb;16(1):61-5
pubmed: 25432664
Br J Dermatol. 2018 May 9;:
pubmed: 29744872
Acta Derm Venereol. 2017 Apr 6;97(4):478-482
pubmed: 27819713
Br J Dermatol. 2016 Aug;175(2):263-72
pubmed: 26873867
JAMA. 2002 Dec 18;288(23):3027-34
pubmed: 12479768
Intensive Care Med. 2012 Mar;38(3):474-81
pubmed: 22258564
JAMA Dermatol. 2018 Mar 1;154(3):330-335
pubmed: 29417136
Med Care. 2009 Aug;47(8):826-34
pubmed: 19584762
J Invest Dermatol. 2018 Jan;138(1):52-57
pubmed: 28942360
J Invest Dermatol. 2013 Jan;133(1):97-103
pubmed: 22931916
Br J Dermatol. 2003 Jul;149(1):211-3
pubmed: 12890229
Br J Dermatol. 2014 Dec;171(6):1434-42
pubmed: 25040429